Impax Laboratories (IPXL): Cutting PT But Reiterating Overweight Rating - Piper Jaffray
Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here.
Piper Jaffray analyst, David Amsellem, reiterated his Overweight rating on shares of Impax Laboratories (NASDAQ: IPXL) after the company Impax reported 2Q16 non-GAAP EPS of $0.21 on revenue of $173M, well short of the Street estimates of $0.32 and $224M, IPXL provided guidance following the announcement of the acquisition of Teva/Actavis generic assets in June, its hard to fathom how it could not have foreseen or known how conditions surrounding key products would further deteriorate.
However, the Teva/Actavis deal represents an upgrade of the generics portfolio. Given that backdrop, the analyst believes the risk/reward profile for IPXL is favorable with a 2017 P/E and EV/ EBITDA of 10x and 9x.
The price target drops to $32 from $40.
Shares of Impax Laboratories closed at $23.43 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Mizuho Securities Downgrades Community Health (CYH) to Underperform
- Jefferies Raises Price Target on Coca Cola (KO) to $46 Following 3Q; Reaffirmed Guidance
- Biogen (BIIB): Mature MS Business - Leerink
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Related EntitiesPiper Jaffray, Definitive Agreement
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!